pharmaceutical investing Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients
LaFleur Minerals Closes LIFE, Flow Thru and Final Hard Dollar Offering for $900,000 to Complete Total of $7,800,421 Funding to Restart Beacon Gold Mill Production Operations in Abitibi Greenstone Belt
Nextech3D.ai Closes Krafty Labs Acquisition Expanding into a Comprehensive End-to-End AI-Powered Live Events and Experiential Engagement Platform
